NEWARK, Del. & WAUWATOSA, Wis.–(BUSINESS WIRE)–Jul 21, 2026–
N-Zyme Biomedical today announced the successful closing of its Series A financing, raising approximately US$4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of its novel pepsin inhibitor platform for reflux disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721835867/en/…